Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting

reversible.

"We are pleased that our SB-509 diabetic neuropathy program Phase 1 update was selected for an oral presentation at the most significant US diabetes meeting of the year," said Edward Lanphier, Sangamo's president and CEO. "We believe that SB-509 represents a new therapeutic approach for diabetic neuropathy, designed to directly protect and possibly restore nerve function, in contrast to the current standard of care designed to address the pain associated with this condition. We expect to provide an additional update on the progress of this trial later in the year. We are encouraged by the data so far and are swiftly moving forward to the next stage of clinical development with our two ongoing Phase 2 clinical trials."

About the SB-509 Clinical Program

SB-509 is an injectable formulation of plasmid DNA that encodes a ZFP TF, designed to upregulate the VEGF-A gene.

Phase 1

Phase 1b study to assess the safety and clinical effects of a single administration of SB-509 to subjects is ongoing. Subjects were randomized and administered either SB-509 or placebo in both legs by intramuscular injection. Two dose levels of SB-509 have been tested. At the first dose level, three subjects were administered placebo and three subjects were treated with a total of 30 mg of SB-509, 15 mg per leg. Accrual of these subjects is complete. A further twenty-two subjects have been treated at the second dose level with either placebo or a total dose of 60 mg of SB-509, administered as 30 mg per leg. Subjects in this Phase 1b study will be monitored for both the safety and tolerability of SB-509 treatment as well as evaluation of pain and clinical effects on lower limb diabetic neuropathy at one, two, three and six months post-treatment.

Phase 2

Sangamo has two ongoing Phase 2 studies in diabetics with sensory/motor neuropathy:

Phase 2 study of SB-509 for mild to moderate DN

The clinical trial is a double-blind, placeb
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
5. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:9/1/2015)... - The unique breadth ... at ESC Congress 2015 provide s ... of manag ing AF in everyday clinical practice across ... first-ever two-year outcomes from the Global Anticoagulant Registry in the Field - Atrial ... most frequent major event in more than 17,000 newly diagnosed AF patients, far ...
(Date:9/1/2015)... Sept. 1, 2015  Based on its ... market, Frost & Sullivan recognizes Pie Medical ... & Sullivan Award for Technology Leadership. ... designed innovative and easy-to-use imaging solutions—its CAAS ... reproducible quantitative results for cardiovascular diagnosis and ...
(Date:9/1/2015)... 2015  Abbott (NYSE: ABT ) announced today positive ... trial comparing the safety and effectiveness of Abbott,s fully ... Abbott,s market-leading, permanent drug eluting stent. The trial was ... and enrolled 400 people with coronary artery disease, ... will be featured at a late-breaking session today at ...
Breaking Medicine Technology:Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 2Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 3Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 4Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 5Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 3Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 4
... Masimo (Nasdaq: MASI ) announced ... Welfare (MHLW) regulatory clearance of its noninvasive and ... the Masimo rainbow SET® platform.  Representing a breakthrough ... hemoglobin level in real-time, SpHb tracks and trends ...
... As US doctors consider the switch from paper charts to ... have teamed up to provide an absolutely free EMR ... only ad-supported EMR platform for medical providers in a sector ... for a five provider practice in the first year. Since ...
Cached Medicine Technology:Masimo Noninvasive and Continuous Hemoglobin Receives Market Clearance in Japan 2Masimo Noninvasive and Continuous Hemoglobin Receives Market Clearance in Japan 3Masimo Noninvasive and Continuous Hemoglobin Receives Market Clearance in Japan 4Can an Ad-Supported EMR Fuel Healthcare's Technology Revolution? 2Can an Ad-Supported EMR Fuel Healthcare's Technology Revolution? 3Can an Ad-Supported EMR Fuel Healthcare's Technology Revolution? 4
(Date:9/1/2015)... ... September 01, 2015 , ... MAP ... the Premier Outcomes-Driven Provider Network. It is the first-ever, standardized, outcomes-driven network ... provision of quality addiction treatment and the utilization of resources to track ...
(Date:9/1/2015)... ... September 01, 2015 , ... Anthony J. Tantillo, Esq., ... Lawyers 2015 for his third consecutive year in a row. Through nomination, research ... helping people. , Born in Niagara Falls, New York, Tantillo is a Buffalo State ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for ... to understand the scope of their EHS regulatory obligations and rapidly collect, share, ...
(Date:8/31/2015)... West Orange, NJ (PRWEB) , ... September 01, ... ... in the spine to eliminate chronic back pain – once required a long, ... with a shorter hospital stay, less pain, less blood loss and minimal muscle ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dental clinicians from ... of Health Sciences to learn more about its integrated approach to diabetes care. ... and Institute of Cellular Medicine at Newcastle University, and Susan Bissett, National Institute ...
Breaking Medicine News(10 mins):Health News:MAP Health Management Launches the MAP Recovery Network 2Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 2Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 3Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 4Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Western Diabetes Institute Collaborates with UK team 2Health News:Western Diabetes Institute Collaborates with UK team 3Health News:Western Diabetes Institute Collaborates with UK team 4
... CHICAGO, Oct. 11 Continuing its efforts ... SAVE THE PATIENT, a,not-for-profit patient-focused organization, is hosting ... Network. "Community Health Hotline" will,air Monday, October 15, ... Monday,s program will feature a frank discussion on ...
... simple tool that can improve the effectiveness of communication ... in dramatic improvements in health and safety. , The ... color images of the medication to be taken each ... a patient,s native language if the patient does not ...
... LOUIS, Oct. 11 KV Pharmaceutical Company,(NYSE: KVa/KVb) ... the Special Committee of the Board of Directors ... On October 11, 2007, KV,s Board of ... submitted findings on the internal,investigation of the Company,s ...
... Society volunteers break, national campaign record for free ... Texas, Oct. 11 High temperatures and intense,sunshine ... Hot Air,Balloon Festival to the Women,s Dermatologic Society ... number of free skin,cancer screenings for this 13th ...
... tests are good front-line tests indicators of heart disease, but ... say. , Thirty percent of all women, for example, ... walk for several minutes at a slightly increasing incline with ... say. , So if you are female, I put you ...
... Oct. 11 Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) ... quarter of 2007 on Wednesday, October 17, 2007 at ... and Chief Executive,Officer, will lead the call. On the ... the third quarter of 2007. The call will ...
Cached Medicine News:Health News:Patient Empowerment -- Medication Error 2Health News:Improving doctor-patient communication yields significant health benefits 2Health News:Improving doctor-patient communication yields significant health benefits 3Health News:Improving doctor-patient communication yields significant health benefits 4Health News:KV Pharmaceutical Company Reports Results of Special Independent Committee Review of Stock Option Grants 2Health News:KV Pharmaceutical Company Reports Results of Special Independent Committee Review of Stock Option Grants 3Health News:KV Pharmaceutical Company Reports Results of Special Independent Committee Review of Stock Option Grants 4Health News:KV Pharmaceutical Company Reports Results of Special Independent Committee Review of Stock Option Grants 5Health News:KV Pharmaceutical Company Reports Results of Special Independent Committee Review of Stock Option Grants 6Health News:Sun Safety Awareness Reaches New Heights at Plano Hot Air Balloon Festival 2Health News:Sun Safety Awareness Reaches New Heights at Plano Hot Air Balloon Festival 3Health News:Taking the stress out of choosing the right stress test 2Health News:Taking the stress out of choosing the right stress test 3Health News:Amylin Pharmaceuticals to Webcast Third Quarter Results 2
Hemagglutination slide test for the qualitative and quantitative detection of Rheumatoid Factor in serum or synovial fluid....
Hemagglutination slide test for the differential qualitative detection and quantitative determination of infectious mononucleosis and other heterophile antibodies in serum or plasma....
Color-enhanced hemagglutination slide test for the rapid qualitative and semi-quantitative detection of infectious mononucleosis heterophile antibodies in serum or plasma....
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
Medicine Products: